Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial Injury
SARS-CoV-2引起的肺内皮损伤的机制和治疗
基本信息
- 批准号:10559640
- 负责人:
- 金额:$ 73.9万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-02-01 至 2026-01-31
- 项目状态:未结题
- 来源:
- 关键词:2019-nCoVACE2AcuteAcute Lung InjuryAcute Respiratory Distress SyndromeAdherens JunctionAffinityBindingBinding ProteinsBiological Response ModifiersBlood VesselsCOVID-19COVID-19 pandemicCOVID-19 severityCOVID-19 treatmentCategoriesCell ReprogrammingCellsCessation of lifeComplementComplicationDataDevelopmentDiseaseDown-RegulationEdemaElementsEndothelial CellsEndotheliumEngineeringEpithelial CellsEpitheliumFunctional disorderGeneticHost DefenseHumanImmuneImmune responseImmune systemInflammasomeInflammatoryInflammatory ResponseInjuryInterferon Type IInterleukin-1 betaInterleukin-6IntravenousK-18 conjugateKnowledgeLiquid substanceLungMediatingMusNaturePathogenicityPatientsPeptide HydrolasesPeptidesPermeabilityPhasePredispositionProteinsResearchRoleRouteSARS-CoV-2 spike proteinSARS-CoV-2 variantSignal TransductionSyndromeTMPRSS2 geneTestingTherapeuticTherapeutic InterventionTissuesTreatment EfficacyUnited StatesVaccinationVaccinesVariantVascular PermeabilitiesViralViral AntigensVirusanakinraantagonistcadherin 5cell injurycell typecellular engineeringcytokinecytokine release syndromeendothelial regenerationhumanized mouselung injurylung vascular injurymortalitymouse modelnovel therapeuticspharmacologicpreventreceptorresponsesevere COVID-19severe injurysingle-cell RNA sequencingtherapeutic targettissue injuryuptakevaccine accessvaccine responsevariants of concern
项目摘要
PROJECT SUMMARY / ABSTRACT
Coronavirus disease 2019 (COVID-19) is a devastating systemic inflammatory syndrome caused by the coronavirus
SARS-CoV-2 which has resulted in over 500,000 deaths in the US during the past year, with this high rate of mortality
being attributed in large part to the development of Acute Lung Injury (ALI) or Acute Respiratory Distress Syndrome
(ARDS). SARS-CoV-2 entry into cells requires the direct binding of the SARS-CoV-2 spike (S)-protein to the principal
host protease-TMPRSS2 and the angiotensin converting enzyme 2 (ACE-2) receptors which are expressed in
multiple host cell types. The development of efficacious vaccines to prevent the spread of SARS-CoV-2 represents
a tremendous advance that will help curb the COVID-19 pandemic, however the emergence of variants of concern
such as the B1.1.7, P1 and B1.351 which can evade the neutralizing responses of the vaccine-induced humoral
immune response underscores the urgent need to develop novel therapeutics to complement the vaccination efforts.
Based on our provocative Supporting Data, we have formulated the overarching hypothesis that SARS-CoV-2
induced lung endothelial injury is a requisite element of COVID-19 induced maladaptive inflammatory injury that can
be therapeutically targeted. We propose the following specific aims: In Aim 1, we will define the nature and underlying
mechanisms of lung endothelial injury underlying COVID-19-induced ALI/ARDS. We will test the hypothesis that the
degree of lung endothelial injury is a key determinant of the overall pathogenicity and mortality of multiple SARS-
CoV-2 variants. We will establish SARS-CoV-2-induced lung vascular injury and compensatory lung endothelial
regeneration using two complementary humanized ACE2 mouse models, EC-specific genetic lineage tracing,
genetic stabilization of VE-cadherin and single cell RNA-Sequencing. In Aim 2, we will define the efficacy and optimal
temporal windows for two targeted pharmacological therapeutic strategies in preventing and resolving SARS-CoV-
2 induced lung endothelial injury. We will test the hypothesis that an engineered soluble hACE-2 peptide has a
higher therapeutic efficacy than the wildtype hACE-2 peptide in reducing lung endothelial injury as well as long-term
EC reprogramming by preventing viral entry and dissemination of multiple SARS-CoV-2 variants. We will test the
corollary hypothesis and that targeted inhibition of IL1β-signaling using a modified IL-1 Receptor antagonist is
protective against the feed-forward inflammatory loop and endothelial injury induced by multiple SARS-CoV2
variants. We will use two hACE-2 mouse models as well as compare distinct routes of delivery (intratracheal versus
intravenous) and identify the optimal temporal windows for the therapeutic intervention.
项目总结/摘要
2019冠状病毒病(COVID-19)是由冠状病毒引起的一种毁灭性的全身炎症综合征
SARS-CoV-2在过去的一年里在美国导致了超过50万人死亡,
在很大程度上归因于急性肺损伤(ALI)或急性呼吸窘迫综合征的发展
(ARDS)。SARS-CoV-2进入细胞需要SARS-CoV-2刺突蛋白直接结合到主要的
宿主蛋白酶-TMPRSS 2和血管紧张素转换酶2(ACE-2)受体,其表达于
多种宿主细胞类型。开发有效的疫苗来预防SARS-CoV-2的传播,
这是一个巨大的进步,将有助于遏制COVID-19大流行,但令人担忧的变种的出现
如B1.1.7、P1和B1.351等,它们能逃避疫苗诱导的体液中和反应,
免疫应答强调了迫切需要开发新的治疗方法来补充疫苗接种的努力。
基于我们的挑衅性支持数据,我们已经制定了总体假设,SARS-CoV-2
诱导的肺内皮损伤是COVID-19诱导的适应不良炎性损伤的必要因素,
成为治疗目标。我们提出了以下具体目标:在目标1中,我们将定义
COVID-19诱导的ALI/ARDS的肺内皮损伤机制。我们将测试假设,
肺内皮损伤程度是多重SARS总体致病性和死亡率的关键决定因素,
CoV-2变种。我们将建立SARS-CoV-2诱导的肺血管损伤和代偿性肺内皮细胞
使用两种互补的人源化ACE 2小鼠模型进行再生,EC特异性遗传谱系追踪,
VE-钙粘蛋白的遗传稳定性和单细胞RNA测序。在目标2中,我们将定义有效性和最佳
两种靶向药物治疗策略预防和缓解SARS-CoV的时间窗
2诱导肺内皮损伤。我们将检验工程化的可溶性hACE-2肽具有
在减少肺内皮损伤以及长期使用中比野生型hACE-2肽具有更高的治疗功效,
通过防止病毒进入和传播多种SARS-CoV-2变异体进行EC重编程。我们将测试
推论假设,并且使用修饰的IL-1受体拮抗剂靶向抑制IL-1 β信号传导,
对多个SARS-CoV 2诱导的前馈炎症环和内皮损伤的保护作用
变体。我们将使用两种hACE-2小鼠模型,并比较不同的递送途径(腹膜内愈合与
静脉内),并确定治疗干预的最佳时间窗。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Asrar B. Malik其他文献
Tissue Regeneration Requires Edema Fluid Clearance by Compensatory Lymphangiogenesis in Zebrafish
斑马鱼的组织再生需要通过补偿性淋巴管生成清除水肿液
- DOI:
- 发表时间:
2024 - 期刊:
- 影响因子:0
- 作者:
Olamide Olayinka;Hannah Ryu;Xiaowei Wang;Asrar B. Malik;Hyun Min Jung - 通讯作者:
Hyun Min Jung
H<sub>2</sub>O<sub>2</sub> and Tumor Necrosis Factor-α Activate Intercellular Adhesion Molecule 1 (ICAM-1) Gene Transcription through Distinct <em>cis</em>-Regulatory Elements within the ICAM-1 Promoter
- DOI:
10.1074/jbc.270.32.18966 - 发表时间:
1995-08-11 - 期刊:
- 影响因子:
- 作者:
Kenneth A. Roebuck;Arshad Rahman;Venkatesh Lakshminarayanan;Kilambi Janakidevi;Asrar B. Malik - 通讯作者:
Asrar B. Malik
Compensatory lymphangiogenesis is required for edema resolution in zebrafish
补偿性淋巴管生成是斑马鱼水肿消退所必需的
- DOI:
10.1038/s41598-025-92970-1 - 发表时间:
2025-03-10 - 期刊:
- 影响因子:3.900
- 作者:
Olamide Olayinka;Hannah Ryu;Xiaowei Wang;Asrar B. Malik;Hyun Min Jung - 通讯作者:
Hyun Min Jung
Functional role of TRPC channels in the regulation of endothelial permeability
- DOI:
10.1007/s00424-005-1461-z - 发表时间:
2005-06-30 - 期刊:
- 影响因子:2.900
- 作者:
Gias U. Ahmmed;Asrar B. Malik - 通讯作者:
Asrar B. Malik
The GTPase Rab1 Is Required for NLRP3 Inflammasome Activation and Inflammatory Lung Injury
GTPase Rab1 是 NLRP3 炎症小体激活和炎症性肺损伤所必需的
- DOI:
10.4049/jimmunol.1800777 - 发表时间:
2018-11 - 期刊:
- 影响因子:4.4
- 作者:
Yuehui Zhang;Lijun Wang;Yang Lv;Chunling Jiang;Guangyu Wu;R;al O. Dull;Richard D. Minshall;Asrar B. Malik;Guochang Hu - 通讯作者:
Guochang Hu
Asrar B. Malik的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Asrar B. Malik', 18)}}的其他基金
iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells
iPSC 衍生的血管化人肺类器官以及肺内皮细胞和肺泡上皮细胞之间的相互作用
- 批准号:
10467249 - 财政年份:2022
- 资助金额:
$ 73.9万 - 项目类别:
iPSC-Derived Vascularized Human Lung Organoids and Interaction Between Lung Endothelial Cells and Alveolar Epithelial Cells
iPSC 衍生的血管化人肺类器官以及肺内皮细胞和肺泡上皮细胞之间的相互作用
- 批准号:
10673199 - 财政年份:2022
- 资助金额:
$ 73.9万 - 项目类别:
E3 Ubiquitin Ligase CHFR Regulates Lung Endothelial Barrier Integrity and Innate Immunity through Control of VE-cadherin Expression
E3 泛素连接酶 CHFR 通过控制 VE-钙粘蛋白表达来调节肺内皮屏障完整性和先天免疫
- 批准号:
10706515 - 财政年份:2022
- 资助金额:
$ 73.9万 - 项目类别:
E3 Ubiquitin Ligase CHFR Regulates Lung Endothelial Barrier Integrity and Innate Immunity through Control of VE-cadherin Expression
E3 泛素连接酶 CHFR 通过控制 VE-钙粘蛋白表达来调节肺内皮屏障完整性和先天免疫
- 批准号:
10494617 - 财政年份:2022
- 资助金额:
$ 73.9万 - 项目类别:
Mechanisms and Treatment of SARS-CoV-2 induced Lung Endothelial Injury
SARS-CoV-2引起的肺内皮损伤的机制和治疗
- 批准号:
10390863 - 财政年份:2022
- 资助金额:
$ 73.9万 - 项目类别:
Amplification Mechanisms of Lung Endothelial Inflammation During Acute Lung Injury
急性肺损伤期间肺内皮炎症的放大机制
- 批准号:
10435435 - 财政年份:2021
- 资助金额:
$ 73.9万 - 项目类别:
Ion Flux Regulation of Macrophage Plasticity in Lung Injury and Repair
肺损伤与修复中巨噬细胞可塑性的离子通量调节
- 批准号:
10701929 - 财政年份:2021
- 资助金额:
$ 73.9万 - 项目类别:
Macrophage Plasticity in Inflammatory Lung Injury
炎症性肺损伤中的巨噬细胞可塑性
- 批准号:
10491049 - 财政年份:2021
- 资助金额:
$ 73.9万 - 项目类别:
相似国自然基金
新型蝙蝠MERS簇冠状病毒HKU5的ACE2细胞受体识别及其分子机制研究
- 批准号:
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
铁皮石斛通过肠道 ACE2 修复 Trp/GPR142 介
导“肠-胰岛 ”轴血糖调控功能的降糖机制研
究
- 批准号:Y24H280055
- 批准年份:2024
- 资助金额:0.0 万元
- 项目类别:省市级项目
CAFs来源的外泌体负性调控ACE2促进肾透明细胞癌癌栓新辅助靶向耐药的机制研究
- 批准号:82373169
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
人类ACE2变构抑制剂的成药性及其抗广谱冠状病毒感染的机制研究
- 批准号:82330111
- 批准年份:2023
- 资助金额:220 万元
- 项目类别:重点项目
新型蝙蝠MERS簇冠状病毒HKU5的ACE2受体识别及细胞入侵机制研究
- 批准号:32300137
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于AT2/ACE2/Ang(1-7)/MAS轴调控心脏-血管-血液系统性重构演变规律研究心衰气虚血瘀证及其益气通脉活血化瘀治法生物学基础
- 批准号:82305216
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
基于外泌体miRNAs介导细胞通讯的大豆ACE2激活肽调控血管稳态机制研究
- 批准号:32302080
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
感毒清经ACE2/Ang(1-7)/MasR信号通路抑制PM2.5诱导慢性气道炎症的机制:聚焦肺泡巨噬细胞极化与“胞葬”的表型串扰
- 批准号:82305171
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
刺参自溶引发机制中ACE2调控靶点的调控网络研究
- 批准号:32372399
- 批准年份:2023
- 资助金额:50 万元
- 项目类别:面上项目
Spike变异对新冠病毒抗原性及ACE2种属嗜性的影响研究
- 批准号:82272305
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
相似海外基金
新型コロナウイルス感染阻害能を有する抗ACE2抗体の阻害機構に関する構造基盤解明
阐明具有抑制新型冠状病毒感染能力的抗ACE2抗体抑制机制的结构基础
- 批准号:
24K09338 - 财政年份:2024
- 资助金额:
$ 73.9万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
ACE2のユビキチン化を介したコロナウイルス感染機構の解明と創薬への挑戦
通过ACE2泛素化阐明冠状病毒感染机制和药物发现的挑战
- 批准号:
22KJ2499 - 财政年份:2023
- 资助金额:
$ 73.9万 - 项目类别:
Grant-in-Aid for JSPS Fellows
ACE2阻害薬およびERK経路阻害薬による慢性腎炎進展抑制効果の検証
ACE2抑制剂和ERK通路抑制剂抑制慢性肾炎进展的效果验证
- 批准号:
23K14982 - 财政年份:2023
- 资助金额:
$ 73.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Large-scale compatibility assessments between ACE2 proteins and diverse sarbecovirus spikes
ACE2 蛋白和多种 sarbecovirus 尖峰之间的大规模兼容性评估
- 批准号:
10722852 - 财政年份:2023
- 资助金额:
$ 73.9万 - 项目类别:
一次線毛とコロナウイルス感染におけるACE2の役割の解明
阐明 ACE2 在原发菌毛和冠状病毒感染中的作用
- 批准号:
22KF0004 - 财政年份:2023
- 资助金额:
$ 73.9万 - 项目类别:
Grant-in-Aid for JSPS Fellows
The regulatory roles of ACE2 and its interaction with Nrf2 in arsenic-induced endothelial dysfunction in experimental and epidemiological studies
实验和流行病学研究中 ACE2 的调节作用及其与 Nrf2 的相互作用在砷诱导的内皮功能障碍中的作用
- 批准号:
23K16310 - 财政年份:2023
- 资助金额:
$ 73.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Role of ACE2 in the mechanism of intestinal regeneration
ACE2在肠道再生机制中的作用
- 批准号:
23K15078 - 财政年份:2023
- 资助金额:
$ 73.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Research and development of a novel pediatric anti-obesity medicine via ACE2 activation in DIZE
通过 DIZE 中 ACE2 激活研发新型儿科抗肥胖药物
- 批准号:
23K15417 - 财政年份:2023
- 资助金额:
$ 73.9万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Lung delivery of novel ACE2 variants for COVID-19
针对 COVID-19 的新型 ACE2 变体的肺部输送
- 批准号:
10483042 - 财政年份:2022
- 资助金额:
$ 73.9万 - 项目类别:
ACE2 on gut barrier dysfunction and BRB disruption
ACE2 对肠道屏障功能障碍和 BRB 破坏的影响
- 批准号:
10535485 - 财政年份:2022
- 资助金额:
$ 73.9万 - 项目类别: